EP1032420A4 - Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee - Google Patents

Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee

Info

Publication number
EP1032420A4
EP1032420A4 EP98958583A EP98958583A EP1032420A4 EP 1032420 A4 EP1032420 A4 EP 1032420A4 EP 98958583 A EP98958583 A EP 98958583A EP 98958583 A EP98958583 A EP 98958583A EP 1032420 A4 EP1032420 A4 EP 1032420A4
Authority
EP
European Patent Office
Prior art keywords
variable region
immunoglobulin molecules
synthetic variable
modified specificity
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98958583A
Other languages
German (de)
English (en)
Other versions
EP1032420A1 (fr
Inventor
Ronald M Burch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of EP1032420A1 publication Critical patent/EP1032420A1/fr
Publication of EP1032420A4 publication Critical patent/EP1032420A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98958583A 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee Withdrawn EP1032420A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US65716P 1997-11-14
US8140398P 1998-04-10 1998-04-10
US81403P 1998-04-10
PCT/US1998/024302 WO1999025378A1 (fr) 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee

Publications (2)

Publication Number Publication Date
EP1032420A1 EP1032420A1 (fr) 2000-09-06
EP1032420A4 true EP1032420A4 (fr) 2004-09-15

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
EP98958584A Withdrawn EP1030684A4 (fr) 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype
EP98958583A Withdrawn EP1032420A4 (fr) 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP98958584A Withdrawn EP1030684A4 (fr) 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype

Country Status (9)

Country Link
EP (2) EP1030684A4 (fr)
JP (2) JP2002507544A (fr)
KR (2) KR20010015818A (fr)
CN (2) CN1327388A (fr)
AU (2) AU763029B2 (fr)
BR (2) BR9815580A (fr)
CA (2) CA2309990A1 (fr)
IL (2) IL136113A0 (fr)
WO (2) WO1999025379A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029443A1 (fr) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Vaccins contraceptifs contenant un anticorps
DK1092779T3 (da) * 1999-10-11 2010-02-15 Pasteur Institut Lentiviirusvektorer til fremstilling af immunterapeutiske præparater
WO2001088159A2 (fr) * 2000-05-16 2001-11-22 Euro-Celtique S.A. Anticorps synthetique cd28 servant a la modulation de responses immunitaires
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE320450T1 (de) 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
WO2003063768A2 (fr) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions et methodes d'inhibition de la toxine du charbon
ATE554787T1 (de) * 2002-04-09 2012-05-15 Univ Missouri Behandlung von typ-1-diabetes vor und nach der expression von prädispositionsmarkern
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (fr) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Procedes utilisant les regles des regions de presentation des anticorps pour intervenir sur des anticorps
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
CA2558813A1 (fr) * 2004-03-09 2005-09-15 Kyoto University Composition medicale contenant un inhibiteur medical cxcr3
JP2008521907A (ja) 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
UA99714C2 (ru) * 2006-08-28 2012-09-25 Ля Хойя Інстітьют Фор Еллерджи Енд Іммьюнолоджи Моноклональное антитело, которое специфически связывается с light
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
CN101970500B (zh) * 2008-03-12 2013-08-14 伊姆克罗尼责任有限公司 抗tyrp1抗体
WO2010126972A1 (fr) * 2009-04-29 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anticorps erg monoclonaux
CN102816240B (zh) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 一种融合蛋白及其融合蛋白表达载体
CA2837472A1 (fr) 2011-05-27 2012-12-06 Fox Chase Cancer Center Anticorps diriges contre le recepteur de type ii d'une substance inhibitrice anti-mullerienne concue de facon rationnelle
WO2013076580A2 (fr) * 2011-11-23 2013-05-30 Bioven 3 Limited Protéines recombinantes et leurs utilisations thérapeutiques
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
CN105705522B (zh) * 2013-05-14 2020-09-15 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
CN103275914B (zh) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 展示保护性抗原的细菌菌蜕及其应用
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
RU2695375C2 (ru) * 2014-05-19 2019-07-23 Вало Терапьютикс Ой Покрытые онколитические аденовирусы для противораковых вакцин
CN105693859B (zh) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 抗人g2a单克隆抗体以及检测人巨噬细胞g2a表达量的试剂盒
CN111978382B (zh) * 2020-09-03 2022-03-04 吉林大学第一医院 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004380A1 (fr) * 1990-09-07 1992-03-19 Unilever Plc Agents de liaison specifiques
WO1992011383A1 (fr) * 1990-12-21 1992-07-09 Celltech Limited ANTICORPS DE RECOMBINAISON SPECIFIQUE AU FNT-$g(a)
WO1994010323A1 (fr) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus comprenant une fraction de liaison modifiee specifique contre des cellules cibles
WO1994014848A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique
WO1994014847A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP0460076B1 (fr) * 1989-02-24 1995-11-29 The Regents Of The University Of California Immunoglobulines ayant subi une manipulation genetique
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004380A1 (fr) * 1990-09-07 1992-03-19 Unilever Plc Agents de liaison specifiques
WO1992011383A1 (fr) * 1990-12-21 1992-07-09 Celltech Limited ANTICORPS DE RECOMBINAISON SPECIFIQUE AU FNT-$g(a)
WO1994010323A1 (fr) * 1992-11-04 1994-05-11 Imperial Cancer Research Technology Limited Virus comprenant une fraction de liaison modifiee specifique contre des cellules cibles
WO1994014848A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique
WO1994014847A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 2, 2000, pages 251 - 253, XP002288085 *
LANZA P ET AL: "ACTIVE IMMUNITY AGAINST THE CDH RECEPTOR BY USING AN ANTIBODY ANTIGENIZED WITH RESIDUES 41-55 OF THE FIRST EXTRACELLULAR DOMAIN", 1 December 1993, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, PAGE(S) 11683-11687, ISSN: 0027-8424, XP000578386 *
LANZA P ET AL: "SELECTIVE INTERACTION OF A CONFORMATIONALLY-CONSTRAINED ARG-GLY-ASP (RGD) MOTIF WITH THE INTEGRIN RECEPTOR ALPHAVBETA3 EXPRESSED ON HUMAN TUMOR CELLS", BLOOD CELLS, MOLECULES AND DISEASES, LAJOLLA, US, vol. 23, no. 12, 30 June 1997 (1997-06-30), pages 230 - 241, XP001193348, ISSN: 1079-9796 *
RIGAUDY P ET AL: "ANTIBODIES SPECIFIC FOR THE NEURONAL FORM OF THE SRC PROTEIN ELICITED BY AN ANTIGENIZED ANTIBODY", 1994, DNA, MARY ANN LIEBERT, NEW YORK, NY, US, PAGE(S) 585-591, ISSN: 1044-5498, XP008032317 *
See also references of WO9925378A1 *
SHARMA J N: "THERAPEUTIC PROSPECTS OF BRADYKININ RECEPTOR ANTAGONISTS", 1993, GENERAL PHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, PAGE(S) 267-274, ISSN: 0306-3623, XP000563698 *
ZANETTI M ET AL: "THEORETICAL AND PRACTICAL ASPECTS OF ANTIGENIZED ANTIBODIES", IMMUNOLOGICAL REVIEWS, MUNKSGAARD, XX, no. 130, December 1992 (1992-12-01), pages 125 - 150, XP008032319, ISSN: 0105-2896 *

Also Published As

Publication number Publication date
EP1030684A1 (fr) 2000-08-30
WO1999025379A1 (fr) 1999-05-27
BR9815580A (pt) 2002-01-29
IL136113A0 (en) 2001-05-20
CA2310269A1 (fr) 1999-05-27
EP1032420A1 (fr) 2000-09-06
AU737457B2 (en) 2001-08-23
AU763029B2 (en) 2003-07-10
AU1459899A (en) 1999-06-07
CN1327388A (zh) 2001-12-19
WO1999025378A1 (fr) 1999-05-27
KR20010015818A (ko) 2001-02-26
AU2003252902A1 (en) 2003-11-06
IL136114A0 (en) 2001-05-20
JP2001526021A (ja) 2001-12-18
WO1999025378A9 (fr) 1999-08-12
CA2309990A1 (fr) 1999-05-27
BR9815289A (pt) 2001-12-26
KR20010015817A (ko) 2001-02-26
CN1294517A (zh) 2001-05-09
JP2002507544A (ja) 2002-03-12
EP1030684A4 (fr) 2004-09-15
AU1459799A (en) 1999-06-07

Similar Documents

Publication Publication Date Title
IL136114A0 (en) Immunoglobulin molecules having a synthetic variable region and modified specificity
GB9810246D0 (en) Clip friction hinge
GB2338952A (en) Synthetic closure
ZA95260B (en) Synthetic receptors libraries and uses thereof
ZA955638B (en) A hair clip
ZA962768B (en) Benzonitriles and benzofluorides
SG79882A1 (en) Protein having tpo activity
EP0856030A4 (fr) Materiau de frottement a base de lignine
GB2290577B (en) Concealed fixing clip
EP0817817A4 (fr) Nouvelles molecules s'opposant a la formation de la glace et leurs applications
GB9613198D0 (en) Clip type fastener
EP0695882A3 (fr) Elément de fixation
EP0772658A4 (fr) Materiau de frottement
GB2320077B (en) Clips
ZA9949B (en) Immunoglobulin molecules having a synthetic variable region and modified specificity.
GB9418579D0 (en) Polymer modified bitumen
AU3000997A (en) Mild synthetic detergent base material and mild synthetic detergent bar produced therefrom
HK1003896A1 (en) Protein having tpo activity
GB9512124D0 (en) Ammoxidation of propane
GB9606327D0 (en) Methacrylated or acrylated cyanoacetates and the adhesives and polymers thereof
GB9420308D0 (en) Clips
GB9515407D0 (en) Synthetic interlinking of molecules
GB9415488D0 (en) Synthetic interlinking of molecules
SG77159A1 (en) Novel anti-clotting molecules and uses therefor
GB9811207D0 (en) Modified immunoglobulin e molecules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1031995

Country of ref document: HK